PYPD
PolyPid Ltd. [PYPD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PYPD Stock Summary
In the News
PYPD Financial details
Company Rating
-
Market Cap
7.61M
Income
-23.87M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-0.47
Forward P/E
-
PEG
-0.02
P/S
-
P/B
3.21
P/C
-
P/FCF
-0.36
Quick Ratio
1.72
Current Ratio
1.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.65
EPS next Y
-
EPS next Q
-
EPS this Y
736.95%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
12.94%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-25%
Inst Own
-
Inst Trans
-
ROA
-115%
ROE
-330%
ROC
-0.79%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.566-14.1
52W High
-79.79%
52W Low
-5.67%
RSI
47
Rel Volume
0.1
Avg Volume
3.35K
Volume
348
Perf Week
-12.38%
Perf Month
-10.16%
Perf Quarter
-20.51%
Perf Half Y
-17.73%
-
-
-
-
Beta
1.414
-
-
Volatility
0.05%, 0.1%
Prev Close
-1.39%
Price
2.83
Change
0.71%
Company Profile
- Volume Average 3.35K
- Market Capitalization 7.61M
- Employee 59
- CEO Ms. Dikla Czaczkes Akselbrad
- Headquarters Petah Tikva,IL
- IPO Date 2020-06-26
-
Website
https://www.polypid.com 
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
